How to Value a Nephrology Practice in 2026

Nephrology is one of the most misunderstood specialties in healthcare M&A. On the surface, a nephrology practice looks like any other physician group — office visits, consultations, hospital rounding. But underneath that clinical layer sits an economic engine that can make nephrology practices extraordinarily valuable: dialysis. Whether a nephrology group owns dialysis centers outright, participates in joint ventures, or holds medical director agreements with DaVita or Fresenius, the dialysis economics fundamentally reshape the valuation.

I've valued nephrology practices from small 2-physician groups worth $2M to multi-site platforms with dialysis JVs worth $50M+. The range is enormous — 5-10x EBITDA — and the spread is almost entirely explained by the dialysis-related revenue streams and the size of the chronic kidney disease patient panel.

Why Nephrology Commands Premium Multiples

Most medical practice specialties trade at 4-7x EBITDA. Nephrology practices with meaningful dialysis economics trade at the top of that range and often above it. Three structural factors drive this premium.

First, the patient base is inherently recurring. Chronic kidney disease is progressive and permanent. A patient diagnosed with Stage 3 CKD will see their nephrologist every 3-6 months for the rest of their life. Stage 4 and 5 patients come in monthly. Dialysis patients are seen multiple times per week. This isn't episodic care — it's a long-term relationship with near-zero churn. Patients don't switch nephrologists casually because the disease management is complex and continuity matters.

Second, dialysis economics are massive. A single dialysis patient generates $80,000-$120,000 per year in treatment revenue (depending on payer mix — Medicare pays roughly $250/treatment, commercial insurance pays $800-2,000+). A 20-station dialysis center running at 85% capacity generates $4-8M in annual revenue with 15-25% margins. If the nephrology group owns or has a JV stake in that center, the value creation is transformative.

Third, supply is constrained. Nephrology has one of the worst physician-to-patient ratios of any specialty. There are approximately 12,000 practicing nephrologists in the US serving 37+ million CKD patients. New nephrologists are not entering the field fast enough — fellowship slots are difficult to fill, and compensation has historically lagged other internal medicine subspecialties. This supply constraint means established practices with large patient panels are genuinely scarce assets.

Dialysis Center Ownership and Joint Ventures

This is where the real value lives in nephrology M&A, and it's where I see the most confusion among buyers who don't understand the specialty.

Wholly-owned dialysis centersare the highest-value asset a nephrology group can hold. A practice that owns and operates its own dialysis centers captures the full treatment revenue, controls the patient experience, and builds an asset that generates substantial EBITDA independent of physician productivity. I've seen nephrology practices where the clinical practice (office visits, consults, hospital rounding) generates $1-2M in EBITDA, but the owned dialysis centers generate $3-5M in additional EBITDA. The dialysis operations can be worth 2-3x the clinical practice itself.

Joint ventures with large dialysis organizations (DaVita, Fresenius, US Renal Care) are more common and still very valuable. In a typical JV, the dialysis organization builds and operates the center, the nephrology group provides the medical director and patient referrals, and profits are split — usually 40-60% to the dialysis org and 40-60% to the physician group, depending on who contributed the patients and who funded the build-out.

JV interests are valued based on the distributions they generate, typically at 6-8x the annual distribution. A JV paying $500K/year in distributions to the nephrology group adds $3-4M to the practice's enterprise value. But buyers need to read the JV operating agreement carefully — many include right of first refusal clauses, change-of-control provisions, or buyout triggers that can complicate or block a transfer to a new owner.

Medical director agreementswithout equity are the least valuable dialysis-related income, but still meaningful. A medical director contract with a dialysis center typically pays $150K-$350K annually for oversight, quality metrics, and patient management. These contracts are personal to the physician and don't always transfer with the practice. I value medical director income at a discount to owned or JV dialysis income because of the transferability risk.

The CKD Patient Panel

Beyond dialysis economics, the size and composition of the CKD patient panel is the primary value driver for the clinical practice component.

A nephrologist with 800-1,200 active CKD patients has a full panel. That panel generates $600K-$1M in annual professional fee revenue through office visits, hospital consults, and procedure fees. More importantly, a percentage of those CKD patients — roughly 5-8% per year — will progress to end-stage renal disease and require dialysis. Each one of those patients represents $80K-$120K in annual dialysis revenue if the practice has dialysis capacity.

The math is powerful. A 5-physician nephrology group with 4,000 active CKD patients will convert roughly 200-320 patients to dialysis annually. If those patients flow into the group's owned or JV dialysis centers, the revenue growth is essentially built in. Buyers underwrite nephrology acquisitions with this progression model because it provides visible, actuarial-grade revenue projections.

Payer mix within the CKD panel matters enormously. Commercial dialysis patients generate 3-8x more revenue than Medicare patients per treatment. A practice with a younger patient population (more commercial insurance) or a geography with strong employer-sponsored coverage will command higher multiples than one with an 85% Medicare payer mix.

Vascular Access: The Overlooked Revenue Stream

Many nephrology practices have developed ancillary procedure revenue through vascular access — the creation and maintenance of fistulas, grafts, and dialysis catheters that patients need for hemodialysis.

Vascular access procedures generate significant revenue per case ($2,500-$8,000 depending on the procedure and setting) with strong margins. A nephrology group that performs its own vascular access — either in an office-based lab or an affiliated ASC — captures revenue that would otherwise go to interventional radiologists or vascular surgeons.

For valuation, vascular access revenue is attractive because it's directly tied to the dialysis patient population and highly recurring (access sites require regular maintenance, thrombectomies, and eventual revisions). A practice performing 400-600 vascular access procedures annually can generate $1-3M in additional revenue, often at 40-50% margins.

The key diligence question is whether the vascular access program is tied to specific physician skills. If only one of five nephrologists is trained and credentialed for interventional procedures, that revenue stream is concentrated and vulnerable. If multiple physicians participate, it's a durable part of the platform.

What Drives Nephrology Value Up

Owned or JV dialysis centers with capacity to grow. A center running at 70% capacity with room for additional stations and shifts is worth more than one at 95% capacity with no expansion path. The buyer sees built-in growth from the existing CKD patient pipeline.

Large CKD patient panel with favorable stage mix. Practices with a high proportion of Stage 3-4 patients have a visible runway of future dialysis conversions. This pipeline is the closest thing to guaranteed future revenue in healthcare.

Multiple physicians with hospital rounding privileges. Hospital rounding is where nephrologists see acute kidney injury patients, many of whom convert to outpatient CKD management. Privileges at multiple hospitals in a market mean the practice has diverse patient acquisition channels that aren't dependent on one referral source.

Value-based care contracts. Nephrology is increasingly moving toward capitated and value-based payment models (CMS CKCC, Strive Health, Somatus partnerships). Practices participating in these models demonstrate forward-thinking management and may capture upside from total cost of care savings.

What Kills Value

No dialysis economics. A nephrology practice that's purely clinical — office visits and hospital rounding with no dialysis ownership, JV, or medical director income — is valued like any other medical practice at 4-6x EBITDA. The premium multiples in nephrology are entirely driven by dialysis-related revenue. Without it, you're buying a physician group, not a kidney care platform.

Physician concentration. If two of five physicians generate 60% of production and both are within 5 years of retirement, the buyer faces a succession crisis that's nearly impossible to solve quickly given nephrology's recruitment challenges. Hiring a new nephrologist takes 12-18 months in most markets, and many candidates want to practice in academic settings rather than community practices.

JV agreements with restrictive change-of-control provisions. If the dialysis JV operating agreement requires DaVita or Fresenius consent for any ownership change — and gives them a right of first refusal at a formula price — the buyer may not actually be able to acquire the most valuable part of the practice. I've seen deals collapse because the JV partner exercised its ROFR and bought the interest directly, leaving the buyer with only the clinical practice at a fraction of the expected value.

Regulatory exposure. Nephrology sits at the intersection of multiple regulatory frameworks — Stark Law, Anti-Kickback Statute, Medicare conditions for coverage, state certificate-of-need laws for dialysis centers. A practice with any history of compliance issues, qui tam lawsuits, or OIG scrutiny creates risk that sophisticated buyers won't touch without a significant discount or extensive representations and warranties.

The Bottom Line

Nephrology practice valuation is a tale of two businesses. The clinical practice — office visits, consults, rounding — is a solid but unremarkable physician group worth 4-6x EBITDA. The dialysis economics — owned centers, JV interests, vascular access programs, medical director contracts — can double or triple the total enterprise value. The practices commanding 8-10x EBITDA have built integrated kidney care platforms where the clinical practice feeds patients into high-margin dialysis and procedure revenue.

For buyers, the diligence priorities are clear: verify the dialysis revenue streams and their transferability, model the CKD patient pipeline, stress-test payer mix assumptions, and confirm that JV agreements allow for ownership transitions. For sellers, the message is equally clear: if you have dialysis economics, make sure buyers understand the full value of what they're acquiring. Too many nephrology groups sell at clinical-practice multiples because they don't properly present the dialysis platform to buyers who understand it.